PMID- 21528640
OWN - NLM
STAT- MEDLINE
DCOM- 20110523
LR  - 20121115
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 61
IP  - 3
DP  - 2011
TI  - Antihypertensive efficacy and safety of benidipine and its effects on cardiac 
      structure and function in elderly Chinese patients with mild to moderate 
      hypertension: an open-label, long-term study.
PG  - 160-6
LID - 10.1055/s-0031-1296183 [doi]
AB  - Benidipine (CAS 91599-74-5) has been reported as an effective antihypertensive 
      treatment and its cardioprotective effects have been shown in several basic and 
      clinical studies. However, the long-term efficacy and safety of benidipine remain 
      unknown in elderly Chinese patient with hypertension. In this prospective, 
      multicenter, open-label clinical trial, 152 eligible patients aged 60 to 75 years 
      with mild to moderate essential hypertension (sitting systolic blood pressure 
      (BP) > or = 140 mmHg and/or sitting diastolic BP > or = 90 mmHg) entered a 
      52-week study. All patients initially received benidipine 2-4 mg once a day, 
      followed by titration to benidipine 8 mg/day to achieve the target BP (< 140/90 
      mmHg in non-diabetics and <130/80 mmHg in diabetics). Add-on hydrochlorothiazide 
      (CAS 58-93-5) and/or metoprolol tartaric acid (CAS 3750-58-6) were permitted 
      during the study. Overall, 132 patients completed the 52-week treatment with 
      benidipine as monotherapy or combination therapy. It showed that the regimen 
      based on benidipine provided an obvious mean trough BP reduction of 13.8 +/- 
      12.4/8.3 +/- 9.2 mmHg (p < 0.001), and 62.5% of patients reached the target BP. 
      In patients with left ventricular hypertrophy, the left ventricular mass index 
      significantly decreased from 147.1 +/- 27.6 g/m2 at baseline to 136.0 +/- 17.5 
      g/m2 at 52 weeks (p = 0.036). Clinical adverse events (AEs) were found in 15.1% 
      of all patients, and six patients discontinued the treatment due to drug-related 
      AEs during the entire trial. Patients' compliance was an average of 98.7%. 
      Benidipine, with a favorable tolerability profile, provides a long-term 
      antihypertensive effect and potential benefit for the heart in elderly patients 
      with mild to moderate hypertensive, suggesting that it is suitable for elderly 
      patients with hypertension.
FAU - Qi, Weilin
AU  - Qi W
AD  - Department of Cardiology, Huashan Hospital of Fudan University, Shanghai, 
      People's Republic of China.
FAU - Fan, Weihu
AU  - Fan W
CN  - RAPID SH Study investigators
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Dihydropyridines)
RN  - 4G9T91JS7E (benidipine)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Calcium Channel Blockers/adverse effects/*therapeutic use
MH  - China
MH  - Dihydropyridines/adverse effects/*therapeutic use
MH  - Echocardiography
MH  - Female
MH  - Heart/*physiopathology
MH  - Heart Function Tests
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hypertension/*drug therapy/pathology/physiopathology
MH  - Hypertrophy, Left Ventricular/pathology/prevention & control
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Myocardium/*pathology
MH  - Patient Compliance
MH  - Prospective Studies
FIR - Fan, W
IR  - Fan W
FIR - Qi, W
IR  - Qi W
FIR - Xi, Y
IR  - Xi Y
FIR - Lu, G
IR  - Lu G
FIR - Liu, Y
IR  - Liu Y
FIR - Li, L
IR  - Li L
FIR - Wu, Z
IR  - Wu Z
FIR - Zhang, Y
IR  - Zhang Y
FIR - Tang, Y
IR  - Tang Y
FIR - Zhang, Y
IR  - Zhang Y
FIR - Zhang, J
IR  - Zhang J
FIR - Liu, R
IR  - Liu R
FIR - Gu, Y
IR  - Gu Y
FIR - Ni, Y
IR  - Ni Y
FIR - Liu, H
IR  - Liu H
FIR - Wu, S
IR  - Wu S
FIR - Xie, Y
IR  - Xie Y
FIR - Huang, H
IR  - Huang H
FIR - Cheng, C
IR  - Cheng C
FIR - Zheng, X
IR  - Zheng X
FIR - Zhang, J
IR  - Zhang J
FIR - Xu, B
IR  - Xu B
FIR - Li, S
IR  - Li S
FIR - He, B
IR  - He B
FIR - Shen, J
IR  - Shen J
FIR - Sun, Y
IR  - Sun Y
FIR - Dai, Q
IR  - Dai Q
FIR - Wang, W
IR  - Wang W
FIR - Wu, Y
IR  - Wu Y
FIR - Li, Y
IR  - Li Y
FIR - Chen, S
IR  - Chen S
FIR - Jiang, J
IR  - Jiang J
FIR - Lu, Q
IR  - Lu Q
FIR - Liu, X
IR  - Liu X
FIR - Chen, T
IR  - Chen T
EDAT- 2011/05/03 06:00
MHDA- 2011/05/24 06:00
CRDT- 2011/05/03 06:00
PHST- 2011/05/03 06:00 [entrez]
PHST- 2011/05/03 06:00 [pubmed]
PHST- 2011/05/24 06:00 [medline]
AID - 10.1055/s-0031-1296183 [doi]
PST - ppublish
SO  - Arzneimittelforschung. 2011;61(3):160-6. doi: 10.1055/s-0031-1296183.